Compare BridgeBio Pharma Inc (BBIO) vs Emerson Electric Co. (EMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Emerson Electric Co. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Emerson Electric Co. trades at $163.98 (market cap $88.53B). The key difference: Emerson Electric Co. is far larger — about 5.3× BridgeBio Pharma Inc's market cap, and Emerson Electric Co. pays a 1.4% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | EMR | |
|---|---|---|
Market Cap | $16.61B | $88.53B |
Sector | Health | Industrials |
52-Week High | $90.17 | $164.38 |
52-Week Low | $47.29 | $123.30 |
Enterprise Value | $18.16B | $99.60B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Emerson Electric (EMR) trades at $158.26, up 0.86% on the day, with a bullish technical signal and strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows robust fundamentals, including a 13.83% net income margin and consistent revenue growth, supported by recent acquisitions like Glue Inc. to enhance AI capabilities. Analyst consensus is positive, with a $171.33 price target indicating potential upside from current levels.
Outlook remains favorable due to organic growth and raised 2026 guidance, but risks include valuation concerns with a P/E of 34.63 and macroeconomic pressures. Investment opportunity hinges on execution in automation and AI segments, while investors should monitor debt levels and competitive dynamics in the industrial sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
